Tara Stephenson

2.0k total citations
33 papers, 308 citations indexed

About

Tara Stephenson is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Tara Stephenson has authored 33 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 16 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Oncology. Recurrent topics in Tara Stephenson's work include Multiple Myeloma Research and Treatments (30 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and CAR-T cell therapy research (10 papers). Tara Stephenson is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and CAR-T cell therapy research (10 papers). Tara Stephenson collaborates with scholars based in United States, Spain and Netherlands. Tara Stephenson's co-authors include Alfred L. Garfall, Niels W.C.J. van de Donk, María‐Victoria Mateos, Arnob Banerjee, Laura Rosiñol, Amrita Krishnan, Raluca Verona, Suzette Girgis, Jesús F. San Miguel and Hareth Nahi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Blood Advances.

In The Last Decade

Tara Stephenson

30 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tara Stephenson United States	9	226	220	133	114	45	33	308
Albert Oriol Rocafiguera Spain	11	240 1.1×	173 0.8×	56 0.4×	172 1.5×	41 0.9×	26	284
Britta Besemer Germany	11	197 0.9×	160 0.7×	66 0.5×	147 1.3×	26 0.6×	37	286
January Baron United States	7	263 1.2×	213 1.0×	85 0.6×	171 1.5×	22 0.5×	12	344
Trisha Piontek United States	6	259 1.1×	210 1.0×	86 0.6×	166 1.5×	23 0.5×	12	339
Joanna Opalińska United States	8	245 1.1×	188 0.9×	90 0.7×	153 1.3×	23 0.5×	27	284
Rossella Troia Italy	10	258 1.1×	171 0.8×	19 0.1×	251 2.2×	24 0.5×	15	330
Danielle Trancucci United States	7	89 0.4×	96 0.4×	54 0.4×	38 0.3×	20 0.4×	14	135
Laura Moreno Spain	6	157 0.7×	106 0.5×	44 0.3×	95 0.8×	52 1.2×	6	220
Francesca Bonello Italy	9	143 0.6×	105 0.5×	28 0.2×	103 0.9×	25 0.6×	18	181
Joshua T. Pearson United States	3	44 0.2×	85 0.4×	53 0.4×	47 0.4×	56 1.2×	4	152

Countries citing papers authored by Tara Stephenson

Since Specialization

Citations

This map shows the geographic impact of Tara Stephenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Stephenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Stephenson more than expected).

Fields of papers citing papers by Tara Stephenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Stephenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Stephenson. The network helps show where Tara Stephenson may publish in the future.

Co-authorship network of co-authors of Tara Stephenson

This figure shows the co-authorship network connecting the top 25 collaborators of Tara Stephenson. A scholar is included among the top collaborators of Tara Stephenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Stephenson. Tara Stephenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Costa, Luciano J., Laura Rosiñol, Rakesh Popat, et al.. (2024). LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES. Hematology Transfusion and Cell Therapy. 46. S515–S515.

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235.

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S548–S548. 8 indexed citations

Popat, Rakesh, Ajay K. Nooka, Niels W.C.J. van de Donk, et al.. (2024). P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S80–S80. 1 indexed citations

Garfall, Alfred L., Lotfi Benboubker, Katarina Uttervall, et al.. (2024). MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S549–S549. 1 indexed citations

Matous, Jeffrey, Albert Oriol, Alfred L. Garfall, et al.. (2024). Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial. Blood. 144(Supplement 1). 4749–4749.

Garfall, Alfred L., Ajay K. Nooka, Niels W.C.J. van de Donk, et al.. (2024). Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7540–7540. 26 indexed citations

Chari, Ajai, Lionel Karlin, Amrita Krishnan, et al.. (2024). Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study. Blood. 144(Supplement 1). 4734–4734. 1 indexed citations

Garfall, Alfred L., Lotfi Benboubker, Katarina Uttervall, et al.. (2024). Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7517–7517. 7 indexed citations

10.

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations

11.

Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S224–S224. 3 indexed citations

12.

Frerichs, Kristine A., Christie P.M. Verkleij, María‐Victoria Mateos, et al.. (2023). P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS. HemaSphere. 7(S3). e5193345–e5193345. 2 indexed citations

13.

Sidana, Surbhi, Philippe Moreau, Alfred L. Garfall, et al.. (2023). P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere. 7(S3). e62475d0–e62475d0. 6 indexed citations

14.

Donk, Niels W.C.J. van de, Alfred L. Garfall, Lotfi Benboubker, et al.. (2023). Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.. Journal of Clinical Oncology. 41(16_suppl). 8033–8033. 16 indexed citations

15.

Bhutani, Manisha, Alfred L. Garfall, Katarina Uttervall, et al.. (2023). P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY. HemaSphere. 7(S3). e90600b0–e90600b0. 1 indexed citations

16.

Donk, Niels W.C.J. van de, Alfred L. Garfall, Lotfi Benboubker, et al.. (2023). P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1. HemaSphere. 7(S3). e43149cb–e43149cb. 3 indexed citations

17.

Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2022). Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Advances. 7(4). 644–648. 30 indexed citations

18.

Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2022). Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Targeted Oncology. 17(4). 433–439. 10 indexed citations

19.

Nooka, Ajay K., Philippe Moreau, Saad Z. Usmani, et al.. (2022). Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. Journal of Clinical Oncology. 40(16_suppl). 8007–8007. 8 indexed citations

20.

Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2021). P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab. Clinical Lymphoma Myeloma & Leukemia. 21. S39–S40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact